Dupuytren's contracture

Endo Announces Publication of New XIAFLEX® (collagenase clostridium histolyticum) Survey Data in Journal of Hand Surgery Global Open

Retrieved on: 
Wednesday, January 24, 2024

DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study .1

Key Points: 
  • DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study .1
    Consensus-based study findings among expert hand surgeons indicate that XIAFLEX® (collagenase clostridium histolyticum) has a wide-ranging application for the appropriate treatment of Dupuytren's contracture in patients with varying degrees of disease severity and functional impairment.
  • Results from the published research indicate a high level of consensus for using XIAFLEX for the treatment of one- or two-finger metacarpophalangeal (MP) joint contractures, most one- or two-finger proximal interphalangeal (PIP) joint contractures, and most combined MP and PIP joint contractures.
  • "Healthcare providers and patients can choose among multiple surgical and nonsurgical treatment options for Dupuytren's disease, and without established guidelines, the process for sorting through those choices can be overwhelming," said Dr. Gary M. Pess, a hand and upper extremity surgeon and lead author of the study.
  • "This study provides insight from experienced hand surgeons about using XIAFLEX to treat varying degrees of Dupuytren's contracture."

Endo Announces Publication of New XIAFLEX® (collagenase clostridium histolyticum) Survey Data in Journal of Hand Surgery Global Open

Retrieved on: 
Wednesday, January 24, 2024

DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study .1

Key Points: 
  • DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study .1
    Consensus-based study findings among expert hand surgeons indicate that XIAFLEX® (collagenase clostridium histolyticum) has a wide-ranging application for the appropriate treatment of Dupuytren's contracture in patients with varying degrees of disease severity and functional impairment.
  • Results from the published research indicate a high level of consensus for using XIAFLEX for the treatment of one- or two-finger metacarpophalangeal (MP) joint contractures, most one- or two-finger proximal interphalangeal (PIP) joint contractures, and most combined MP and PIP joint contractures.
  • "Healthcare providers and patients can choose among multiple surgical and nonsurgical treatment options for Dupuytren's disease, and without established guidelines, the process for sorting through those choices can be overwhelming," said Dr. Gary M. Pess, a hand and upper extremity surgeon and lead author of the study.
  • "This study provides insight from experienced hand surgeons about using XIAFLEX to treat varying degrees of Dupuytren's contracture."

Endo Announces New Data for Dupuytren's Contracture Presented at the American Association for Hand Surgery Annual Meeting

Retrieved on: 
Friday, January 19, 2024

DUBLIN, Jan. 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX® (collagenase clostridium histolyticum) were shared during the American Association for Hand Surgery (AAHS) annual meeting.

Key Points: 
  • DUBLIN, Jan. 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX® (collagenase clostridium histolyticum) were shared during the American Association for Hand Surgery (AAHS) annual meeting.
  • Endo provided funding through an investigator-initiated research grant.
  • "This medical knowledge presented at the AAHS annual meeting may help healthcare providers treat patients with Dupuytren's contracture and, hopefully, improve patient outcomes," said Dr. Jason Nydick, an orthopedic hand surgeon at Florida Orthopaedic Institute in Tampa, Florida and lead investigator of the studies.
  • "The results related to the effective treatment of the proximal interphalangeal (PIP) joint with XIAFLEX are particularly noteworthy."

Endo Announces New Data for Dupuytren's Contracture Presented at the American Association for Hand Surgery Annual Meeting

Retrieved on: 
Friday, January 19, 2024

DUBLIN, Jan. 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX® (collagenase clostridium histolyticum) were shared during the American Association for Hand Surgery (AAHS) annual meeting.

Key Points: 
  • DUBLIN, Jan. 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX® (collagenase clostridium histolyticum) were shared during the American Association for Hand Surgery (AAHS) annual meeting.
  • Endo provided funding through an investigator-initiated research grant.
  • "This medical knowledge presented at the AAHS annual meeting may help healthcare providers treat patients with Dupuytren's contracture and, hopefully, improve patient outcomes," said Dr. Jason Nydick, an orthopedic hand surgeon at Florida Orthopaedic Institute in Tampa, Florida and lead investigator of the studies.
  • "The results related to the effective treatment of the proximal interphalangeal (PIP) joint with XIAFLEX are particularly noteworthy."

Global Dupuytren's Disease Market Analysis Report 2023-2030: Adalimumab Emerges as Cost-Effective Treatment for Early-Stage Disease - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 12, 2023

This projected market expansion highlights the growing recognition of the importance of addressing and treating this condition effectively.

Key Points: 
  • This projected market expansion highlights the growing recognition of the importance of addressing and treating this condition effectively.
  • Consequently, intensified research and development efforts are anticipated in the near future, leading to advancements in treatment options and potential breakthroughs in managing Dupuytren's disease.
  • In a recent study, adalimumab emerged as a potentially cost-effective treatment choice during the early stages of Dupuytren's disease.
  • These results underscore the potential advantages of adalimumab as a practical and economically viable treatment option specifically for individuals in the early stages of Dupuytren's disease.

Endo Announces First Patient Enrolled in Registry of Dupuytren's Contracture

Retrieved on: 
Monday, June 26, 2023

DUBLIN, June 26, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in GRASP-DC (Generating Real-world Ambispective data to Study Participant Treatment outcomes for Dupuytren's Contracture), a non-interventional registry of up to 1,000 patients with Dupuytren's contracture (DC).

Key Points: 
  • DUBLIN, June 26, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in GRASP-DC (Generating Real-world Ambispective data to Study Participant Treatment outcomes for Dupuytren's Contracture), a non-interventional registry of up to 1,000 patients with Dupuytren's contracture (DC).
  • This registry will create the largest and most comprehensive collection of real-world DC data on treatment outcomes.
  • "We're pleased to support this unprecedented effort to help advance understanding and treatment of Dupuytren's contracture," said Gregory Kaufman, M.D., Vice President, Medical Affairs and Chief Medical Officer at Endo.
  • "Along with our study steering committee partners, Endo is committed to supporting the Dupuytren's patient community."

Endo Announces First Patient Enrolled in Registry of Dupuytren's Contracture

Retrieved on: 
Monday, June 26, 2023

DUBLIN, June 26, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in GRASP-DC (Generating Real-world Ambispective data to Study Participant Treatment outcomes for Dupuytren's Contracture), a non-interventional registry of up to 1,000 patients with Dupuytren's contracture (DC).

Key Points: 
  • DUBLIN, June 26, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in GRASP-DC (Generating Real-world Ambispective data to Study Participant Treatment outcomes for Dupuytren's Contracture), a non-interventional registry of up to 1,000 patients with Dupuytren's contracture (DC).
  • This registry will create the largest and most comprehensive collection of real-world DC data on treatment outcomes.
  • "We're pleased to support this unprecedented effort to help advance understanding and treatment of Dupuytren's contracture," said Gregory Kaufman, M.D., Vice President, Medical Affairs and Chief Medical Officer at Endo.
  • "Along with our study steering committee partners, Endo is committed to supporting the Dupuytren's patient community."

Endo to Cease Production and Sale of Qwo® (collagenase clostridium histolyticum-aaes)

Retrieved on: 
Tuesday, December 6, 2022

DUBLIN, Dec. 6, 2022 /PRNewswire/ -- Endo International plc(OTC: ENDPQ) announced today that it will cease the production and sale of Endo Aesthetics' Qwo (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration.

Key Points: 
  • DUBLIN, Dec. 6, 2022 /PRNewswire/ -- Endo International plc(OTC: ENDPQ) announced today that it will cease the production and sale of Endo Aesthetics' Qwo (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration.
  • "After careful consideration, we have determined that QWO does not represent a viable commercial opportunity for Endo," said Blaise Coleman, President and CEO of Endo.
  • Qwo is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women.
  • If such a reaction occurs, further injection of QWO should be discontinued and appropriate medical therapy immediately instituted.

Endo to Cease Production and Sale of Qwo® (collagenase clostridium histolyticum-aaes)

Retrieved on: 
Tuesday, December 6, 2022

DUBLIN, Dec. 6, 2022 /PRNewswire/ -- Endo International plc(OTC: ENDPQ) announced today that it will cease the production and sale of Endo Aesthetics' Qwo (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration.

Key Points: 
  • DUBLIN, Dec. 6, 2022 /PRNewswire/ -- Endo International plc(OTC: ENDPQ) announced today that it will cease the production and sale of Endo Aesthetics' Qwo (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration.
  • "After careful consideration, we have determined that QWO does not represent a viable commercial opportunity for Endo," said Blaise Coleman, President and CEO of Endo.
  • Qwo is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women.
  • If such a reaction occurs, further injection of QWO should be discontinued and appropriate medical therapy immediately instituted.

Endo Launches Unscripted Video Series With Real Dupuytren's Contracture Patients

Retrieved on: 
Wednesday, October 5, 2022

DUBLIN, Oct. 5, 2022 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today the launch of its new branded video series, Coffee & Cords, which aims to educate people about Dupuytren's contracture (DC), a progressive hand condition that results in the formation of a collagen rope-like cord that pulls fingers toward the palm and affects an estimated 14 million Americans.

Key Points: 
  • Talk to your healthcare provider if you have a problem with your blood clotting.
  • Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.
  • Endo expressly disclaims any intent or obligation to update these forward-looking statements, except as required to do so by law.
  • Copies of Endo's press releases and additional information about Endo are available at www.endo.com or you can contact the Endo Investor Relations Department at [email protected] .